Cannabis Report
Home > Boards > US OTC > Medical - Drugs >

OncBioMune Pharmaceuticals Inc. (OBMP)

OBMP RSS Feed
Add OBMP Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, Weedman1
Search This Board: 
Last Post: 7/21/2018 11:51:15 AM - Followers: 117 - Board type: Free - Posts Today: 3

Image result for biotech

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology that is designed to stimulate the immune system to selectively attack cancer cells without harm to the patient. The vaccine technology has been proven safe through use in more than 300 patients without a single serious adverse event. Our lead product, ProscaVax™ for prostate cancer, is near conclusion of a Phase 1 trial funded by the Department of Defense Navy Cancer Vaccine Program. Based upon data showing ProscaVax is non-toxic and can lower PSA levels, we are moving ProscaVax into a Phase 2 trial for prostate cancer patients in the “Active Surveillance” category, an early stage of disease for which there are currently no treatments without significant morbidities. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs, including paclitaxel (Abraxane).  


 





Press releases: http://oncbiomune.com/news/

SEC Filings: https://www.sec.gov/cgi-bin/browse-edgar?company=oncbiomune&owner=exclude&action=getcompany

Quote: https://www.otcmarkets.com/stock/OBMP/overview

Clinical trials: 
 https://clinicaltrials.gov/ct2/results?cond=&term=oncbiomune&cntry=&state=&city=&dist=





CHIEF LEADERSHIP

 

Image result for Dr. Jonathan Head

Dr. Jonathan Head, Ph.D.

  

CHIEF EXECUTIVE OFFICER, CHAIRMAN

Dr. Head has been instrumental in the development of our new chemotherapy and immunotherapy programs. Dr. Head and Dr. Elliott are the co-developers and patent holders of one of the first patented autologous breast cancer vaccines in the United States.  His major goal is to implement translational research – the movement of laboratory-developed technologies into the clinical setting.  This is the taking of new therapies from cell culture to an accepted therapy for cancer patients.

As a tumor cell biologist, Dr. Head’s specialties include:

Cell culture research
Animal research
Human clinical research
Innovative chemotherapies
Immunotherapy/cancer vaccines
Oncogene and antisense research
Tumor markers

Dr. Head is an Adjunct Associate Professor of Biochemistry at Tulane University School of Medicine, an Adjunct Professor of Physical and Biological Sciences at Delta State University and an Adjunct Associate Professor at Louisiana State University School of Veterinary Medicine.   He is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Although patients rarely meet Dr. Head, the new treatments we offer are the result of his and Dr. Elliott’s work.

 
 



Image result for Dr. Robert Elliott


Dr. Robert Elliott, M.D., Ph.D.

 
 

CHIEF MEDICAL OFFICER

Dr. Robert Elliott is the driving force behind our The Elliott-Elliott-Head Breast Cancer Research and Treatment Center.  Colleagues often remark that his energy seems boundless. Indeed, it often is.

In 1973, when the Center was founded, Dr. Elliott’s dream was to create the finest center for total breast care. With that step behind us, the dream continues.  Dr. Elliott continues doing research to discover new treatments and drug therapies, and has implemented a team approach to bring total breast care to the patients.

Dr. Elliott sees patients from all over Louisiana, the Southeast and across the United States. He collaborates on research projects with other scientists around the world. Dr. Elliott has spoken to medical audiences in the United States and Europe and has authored many papers and abstracts. He has also published a book, Breast Cancer, Anger at the Enemy, which deals with the lack of total breast care available for women. He shares his own frustration and heartaches of caring for dying cancer patients as they struggle for survival, and finally sends a message of hope as he and his research team search for a cure for breast cancer.

Trained as a general surgeon, Dr. Elliott feels that breast care should be a specialty of itself, with patients being able to receive the highest quality of care from one physician who reads their mammograms, examines them, performs their surgery and administers their therapies.

To advance this concept and to share his experience with other physicians like himself who specialize in breast care, Dr. Elliott founded the American Mastology Association. He currently serves as President of this society. In spite of a busy calendar of meetings and research, Dr. Elliott’s first love is his patients. He devotes the majority of his time to the Center and to helping women overcome breast disease.


 
Andrew Kucharchuk
 

CHIEF FINANCIAL OFFICER, PRESIDENT, DIRECTOR

Andrew “Al” Kucharchuk is a graduate of Louisiana State and Tulane Universities Freeman School of Business, where he earned an MBA with a Finance Concentration. He currently serves as the Company’s Chief Financial Officer and oversees the business and administrative processes.  In addition to these duties, Al also directs business development efforts including the expansion of operations to accommodate increased research and clinical development. Al has assisted Dr. Head in the administration of the three contracts that have lead to the clinical studies for the Company’s lead product, ProscaVax™.

Mr. Kucharchuk is a member of Kappa Alpha Order fraternity. He lives in Baton Rouge with his wife Jessica and their sons Henry and Davis.

 
 

Charles L. Rice, Jr.

 
DIRECTOR

Mr. Rice is the President and Chief Executive Officer of Entergy New Orleans, Inc., an $800 million a year electric and gas utility and subsidiary of NYSE-listed Entergy Corporation.  After his first legal private practice position in Louisiana with Jones, Walker, Waechter, Poitevent, Carrere & Denegre, L.L.P, Rice joined Entergy in the legal department in 2000, serving as senior counsel in the Entergy Services, Inc. litigation group and then as manager of labor relations litigation support in human resources.

Rice was recruited into New Orleans city government in 2002 as the city attorney and later took the critical role of chief administrative officer for the City of New Orleans, where he managed 6,000 employees and the city’s $600 million budget. In 2005, the law firm of Barrasso, Usdin, Kupperman, Freeman & Sarver, L.L.C. recruited him back to private practice, where he was named partner.

Returning to Entergy in 2009, Rice served as director of utility strategy where he was responsible for coordinating regulatory, legislative, and communications efforts to develop and execute strategies that advanced commercial objectives for the company’s regulated service areas. He then served as director of regulatory affairs for Entergy New Orleans.

Rice holds a bachelor’s degree in business administration from Howard University, a juris doctorate from Loyola University’s School of Law and master’s degree in business administration from Tulane University. After graduating from Howard University, he was commissioned as a second lieutenant in the United States Army and served as a military intelligence officer with the 101st Airborne Division (Air Assault) at Fort Campbell, KY. While in the Army, he earned the Airborne Badge, Air Assault badge and was awarded the Army Commendation and the Army Achievement medals.

He is a member of the Alabama and Louisiana State Bar Associations, the American Bar Association, the New Orleans Bar Association, and the National Bar Association.

 
 

Daniel Hoverman


DIRECTOR

Daniel Hoverman is a Director at NYSE-listed Houlihan Lokey, a leading global investment bank, where he is a senior member of the firm’s Corporate Finance Group. Mr. Hoverman is also actively involved with Houlihan Lokey’s efforts in equity capital markets.

Mr. Hoverman has extensive mergers and acquisitions advisory and financing experience, having completed over $100 billion of transactions for both private and public companies across multiple industries and geographies. Before joining Houlihan Lokey, he was a Director with Credit Suisse in Hong Kong as a member of the office of the General Counsel, and was responsible for oversight and management of investment banking transactions. Prior to Credit Suisse, he was a Director with UBS Investment Bank in New York as a member of the firm’s Equity Capital Markets Group and Equity Corporate Finance Team, where he was responsible for origination, oversight and management of securities offerings. He began his career with Kirkland & Ellis LLP as a corporate attorney focusing on capital markets and mergers and acquisition transactions.

Mr. Hoverman received a B.A. from Yale University, where he graduated cum laude with distinction in history and was a Robert C. Bates Fellow and New Prize recipient, and received a J.D. and M.B.A. from Columbia University, where he was a James Kent Scholar and a John C. Olin Fellow. Mr. Hoverman holds Series 7, 24, 63 and 79 licenses and the designation of Chartered Financial Analyst, and is an inactive member of the New York Bar.




Dr. J. Jacques Carter

 

SCIENTIFIC ADVISORY BOARD MEMBER

Dr. Carter currently serves as a physician at the Beth Israel Deaconess Medical Center in Boston, MA and is an assistant professor at Harvard Medical School. From 2005 to 2014, he also served as the Medical Director of the Prostate Cancer Screening and Education Program at the Dana-Farber Cancer Institute.

Dr. Carter completed his residency training in Internal Medicine at Beth Israel Deaconess Medical Center in Boston, followed by a graduate program at the Harvard School of Public Health, where he received his MPH degree. He then completed a clinical fellowship in Primary Care Medicine at the Massachusetts General Hospital.

Dr. Carter has held a number of clinical and administrative positions, including Medical Directorships of several local and national health care organizations. A former director of one of the major clerkships, he now serves as a teacher/advisor/mentor for students at Harvard Medical School and the Harvard School of Public Health. Dr. Carter has been active in a number of civic and community organizations, including past president of the board of Family Service of Greater Boston and past chair of the Brookline Advisory Council on Public Health. He regularly gives talks on medical and health related issues to community groups and students throughout greater Boston. He also lectures nationally and internationally on medical and public health topics. Dr. Carter serves as a medical consultant and resource for members of the media. He is a past President of the Harvard School of Public Health Alumni Association and a current director of the Harvard Alumni Association. Dr. Carter is a founding member of the Georgetown University African American Advisory Board. He is the recipient of the 2010 Harvard Medical School/Harvard School of Dental Medicine Community Service Lifetime Achievement Award. His bio has been included in “Who’s Who in the East, “Who’s Who in Medicine and Healthcare”, Who’s Who in Science and Engineering, and “Who’s Who in America”.



OBMP pipeline
 

http://oncbiomune.com/pipeline/
 

¹Upon completion of a successful Phase 1 study, the Company plans to begin a Phase 2 study at Harvard Cancer Centers.

 

Phase 2 clinical trial of ProscaVax for early-stage prostate cancer to be hosted at Beth Israel Deaconess Medical Center a teaching hospital of Harvard University Medical School in Boston, MA.

ProscaVax is OncBioMune’s lead immunotherapy platform candidate consisting of a combination of prostate cancer associated prostate specific antigen (PSA) with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

Per the study protocol, patients to be enrolled will be in what is termed “active surveillance,” a disease management option for patients with localized prostate cancer that elect to work with their doctor to monitor the disease for progression before taking more drastic intervention measures, such as surgery or radiotherapy.  To the Company’s knowledge, the trial of ProscaVax is the first ever worldwide for a prostate cancer vaccine technology addressing the active surveillance patient population.

http://oncbiomune.com/2018/06/20/oncbiomune-to-commence-phase-2-trial-of-proscavax-for-early-stage-prostate-cancer-patients/


Concurrent with the Phase 2 trial of patients in active surveillance, the Company is undergoing the approval process to initiate a Phase 2 trial of ProscaVax in hormone-naïve recurrent prostate cancer patients with increasing PSA at the Urology Clinics of North Texas.

 
 
 

OBMP Daily Chart





 

OBMP Weekly Chart



 

OBMP SECURITY DETAILS

Share Structure

 
Authorized Shares
500,000,000
Outstanding Shares
223,744,842
Restricted
117,530,685
Unrestricted
89,207,059
Held at DTC
89,059,869
Float
9,773,505
https://www.otcmarkets.com/stock/OBMP/security

Last 10-Q

https://www.sec.gov/Archives/edgar/data/1362703/000149315218008916/form10-q.htm
 
 
Contact:
http://oncbiomune.com/
OncBioMune Pharmaceuticals, Inc.
Jonathan Head, Phd
Chief Executive officer and Chairman
Jhead@oncbiomune.com                 Image result for biotech


 

 

Cannabis Report
OBMP
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OBMP News: Amended Current Report Filing (8-k/a) 07/02/2018 04:49:07 PM
OBMP News: Quarterly Report (10-q) 06/19/2018 03:24:09 PM
OBMP News: Annual Report (10-k) 05/31/2018 05:16:14 PM
OBMP News: Initial Statement of Beneficial Ownership (3) 05/22/2018 05:25:40 PM
OBMP News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/16/2018 04:24:20 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#6310  Sticky Note Here is some DD research on patients all tr1205 07/19/18 01:03:57 PM
#3852  Sticky Note OncBioMune setting up for 2 Phase 2 trials BooDog 05/10/18 10:16:48 AM
#6330   I am new to investing in penny stocks, Tanker12 07/21/18 11:51:15 AM
#6329   I am very comfortable with what is posted southerngent1 07/21/18 09:38:40 AM
#6328   Impressive? He clicked on the U.S. Patent learningcurve2020 07/21/18 09:35:53 AM
#6327   I think we will see the whale buyers jcbaby 07/20/18 11:56:09 PM
#6326   The Sticky Notes are the Yellow Highlighted messages CanItBThisEZ2Make 07/20/18 08:02:52 PM
#6325   Thanks for the complement! I think it tr1205 07/20/18 07:34:36 PM
#6324   Yes, this truly is some impressive DD! I Badge04 07/20/18 06:21:56 PM
#6322   OK Dumb question... what is a sticky board? Tanker12 07/20/18 04:55:38 PM
#6321   Post #6310 has now been added to the Weedman1 07/20/18 01:36:11 PM
#6320   Great job on the patents research. Thanks to avocato 07/20/18 09:59:52 AM
#6319   I will say...you are a man of few Badge04 07/20/18 08:36:20 AM
#6318   $$$ OBMP $$$ Moe money 02 07/20/18 08:21:39 AM
#6317   Thanks, I appreciate the compliments. I don’t tr1205 07/20/18 01:14:09 AM
#6316   Impressive. learningcurve2020 07/19/18 10:01:04 PM
#6315   Nice Post, Definitely worth a sticky. CanItBThisEZ2Make 07/19/18 07:06:00 PM
#6314   Thanks for pointing out to everyone the market CanItBThisEZ2Make 07/19/18 07:02:34 PM
#6313   No it expired in 2014. No offense Al, but learningcurve2020 07/19/18 02:04:19 PM
#6312   Thanks. That's good but keep in mind learningcurve2020 07/19/18 01:50:32 PM
#6311   LC upon seeing your post I have communicated southerngent1 07/19/18 01:05:00 PM
#6310   Here is some DD research on patients all tr1205 07/19/18 01:03:57 PM
#6309   $OBMP on watch GemsBond 07/19/18 11:38:07 AM
#6308   Three patents one expired. Question is how learningcurve2020 07/19/18 10:45:55 AM
#6307   with these thin walls and we are going jcbaby 07/19/18 10:37:02 AM
#6306   That's a great question the company should be avocato 07/19/18 10:27:28 AM
#6305   The question is where is the patent attached Abigail2 07/19/18 10:00:36 AM
#6304   You seem like a very sophisticated investor. learningcurve2020 07/19/18 09:32:17 AM
#6303   Incorrect. Company goes out you lose. learningcurve2020 07/19/18 09:29:36 AM
#6302   Guess math is out of the question here. learningcurve2020 07/19/18 09:26:19 AM
#6301   After sleeping on this video I just had Tanker12 07/19/18 07:14:37 AM
#6300   once the big volume puppies come a calling jcbaby 07/18/18 10:41:51 PM
#6299   no one loses money in a stock until jcbaby 07/18/18 10:37:22 PM
#6297   If you are really telling the truth that southerngent1 07/18/18 10:16:15 PM
#6296   Whats "yeah yeah"? I really dont care southerngent1 07/18/18 10:13:37 PM
#6295   Yeah yeah. learningcurve2020 07/18/18 08:33:47 PM
#6294   Whether you bought at $1, 50 cents or learningcurve2020 07/18/18 08:33:10 PM
#6293   WOW!! what a powerful video. Puts a very Tanker12 07/18/18 07:58:29 PM
#6292   I swung back 291k today, most for 0.023. CanItBThisEZ2Make 07/18/18 06:58:52 PM
#6291   Found it! This is the video that first tr1205 07/18/18 06:52:58 PM
#6290   With a $16-18B market and 6% CAGR it’s tr1205 07/18/18 06:31:45 PM
#6289   Roger that tr1205 07/18/18 06:19:05 PM
#6288   I have been saying for a long time Tanker12 07/18/18 06:17:07 PM
#6287   Phase 2 timeline estimates, from clinical trails website: tr1205 07/18/18 04:28:31 PM
#6286   Larry, I haven't lost a dime yet. In southerngent1 07/18/18 04:21:38 PM
#6285   @learningcurve - 90%+ from what high? What was StoneStreetProsper 07/18/18 03:27:09 PM
#6284   Onc if you've lost more than ninety percent yet. learningcurve2020 07/18/18 03:12:14 PM
#6283   I take it you don't work at Hallmark. southerngent1 07/18/18 09:46:33 AM
#6282   Just like it did for Harvard? Let's learningcurve2020 07/18/18 09:39:10 AM
#6281   I hope an update on the north Texas southerngent1 07/18/18 08:53:20 AM
#6280   Thus far strictly the latter. southerngent1 07/18/18 08:51:28 AM
#6279   Just curious for those that have been invested Badge04 07/18/18 08:31:38 AM
PostSubject